• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

    2/14/22 3:27:23 PM ET
    $CLBS
    Managed Health Care
    Health Care
    Get the next $CLBS alert in real time by email
    SC 13G/A 1 tm226115d20_sc13ga.htm SC 13G/A

     

    CUSIP No: 128058203

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Caladrius Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    128058203
    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨  Rule 13d-1(b)
      x  Rule 13d-1(c)
      ¨  Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 128058203

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

     

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    1,575,000
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    1,575,000

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        1,575,000
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        2.6%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 128058203

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

     

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    1,575,000
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    1,575,000

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        1,575,000
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        2.6%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 128058203

     

    Item 1.

     

    (a)Name of Issuer

     

    Caladrius Biosciences, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    110 Allen Road, Second Floor, Basking Ridge, NJ 07920

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e) CUSIP Number

     

    128058203

     

     

     

     

    CUSIP No: 128058203

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 indicates there were 59,779,855 Shares outstanding as of November 4, 2021.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No: 128058203

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 128058203

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed
      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 128058203

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed 

     

     

     

    Get the next $CLBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CLBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

      Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius") and Cend Therapeutics, Inc. ("Cend") today announced that the proposed merger of the two companies has closed following the approval of Caladrius' stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc.

      9/15/22 9:15:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

      BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics ("Cend"), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius' common stock to Cend's stockholders pursuant to the Agreement and Plan of Merge

      9/14/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

      BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York City (Hybrid conference)Presentation format: In-person and live/archived webcastPresentation Date/Time: Wednesday, September 14, 2022, at 12:00 p.m. ESTWebcast Link: https://bit.ly/3ARcXnjFor m

      9/8/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      2/14/22 3:27:23 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      2/10/22 3:46:07 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      1/19/22 10:44:54 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CLBS
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/17/23 5:05:25 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/12/23 4:02:08 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form 4: Ruoslahti Erkki was granted 20,000 shares

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/11/23 4:20:29 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

      MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently serving as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ:CLBS). "Mr. Girolamo will bring invaluable legal, finance and biopharmaceutical development insight and leadership to our Board," said

      2/17/22 8:00:00 AM ET
      $CLBS
      $LGVN
      Managed Health Care
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

      BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company's Chief Medical Officer ("CMO"). Dr. Buck joins Caladrius from ICON plc ("ICON"), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. During her time at ICON, Dr. Buck served as its CMO, where she represented the company's position on key scientific, ethical, and medical govern

      9/1/21 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

      NEW YORK, Dec. 2, 2020 /PRNewswire/ -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer. "We're pleased to welcome Joe to the HiberCell team and have Ari take on an expanded role as chief business officer," said Alan C. Rigby, Ph.D., co-founder and chief executive officer of HiberCell. "Joe has a track record of successful financial leadership and we're pleased to have him on board during a tremendous period of organizational growth. As a co-founder o

      12/2/20 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital Management reiterated coverage on Caladrius Biosciences with a new price target

      Brookline Capital Management reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/9/21 8:09:13 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Brookline Capital reiterated coverage on Caladrius Biosciences with a new price target

      Brookline Capital reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/3/21 12:13:10 PM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Caladrius Biosciences Inc.

      10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      11/10/22 4:12:58 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      11/10/22 4:10:40 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form S-8 filed by Caladrius Biosciences Inc.

      S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      10/17/22 4:02:44 PM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Financials

    Live finance-specific insights

    See more
    • Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our

      8/4/22 4:05:00 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

      BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d

      7/28/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

      Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a conference call tomorrow, May 24th at 8:15 a.m. EDT BASKING RIDGE, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as

      5/23/22 4:05:00 PM ET
      $CLBS
      Managed Health Care
      Health Care